Article
Outcomes of Patients with RAS-Positive Bethesda III and IV Cytology Thyroid Nodules.
Thyroid : official journal of the American Thyroid Association - 1 Apr 2026
Wu Jiahui, Yeo Caitlin, Qi Jackson, Ghaznavi Sana, Khalil Moosa, Nohr Erik, Box Adrian, Eszlinger Markus, Paschke Ralf
Abstract excerpt
BACKGROUND: Routine resection of all RAS-positive nodules may result in overtreatment for up to 50% of patients. We evaluated the management strategy and outcomes of RAS-positive nodules. METHODS: Following implementation of reflexive ThyroSPECTM molecular testing (MT) for all Bethesda III and IV thyroid nodules in July 2020, we identified patients with isolated RAS mutations between July 30, 2020, and September...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.